These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 36077660)

  • 1. Recent Trends in Nanomedicine-Based Strategies to Overcome Multidrug Resistance in Tumors.
    Khan MM; Torchilin VP
    Cancers (Basel); 2022 Aug; 14(17):. PubMed ID: 36077660
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel nanomedicines to overcome cancer multidrug resistance.
    Su Z; Dong S; Zhao SC; Liu K; Tan Y; Jiang X; Assaraf YG; Qin B; Chen ZS; Zou C
    Drug Resist Updat; 2021 Sep; 58():100777. PubMed ID: 34481195
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug Resistance in Metastatic Breast Cancer: Tumor Targeted Nanomedicine to the Rescue.
    Gote V; Nookala AR; Bolla PK; Pal D
    Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33925129
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overcoming multidrug resistance with nanomedicines.
    Ganoth A; Merimi KC; Peer D
    Expert Opin Drug Deliv; 2015 Feb; 12(2):223-38. PubMed ID: 25224685
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
    Pérez-Herrero E; Fernández-Medarde A
    Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nanomedicines for combating multidrug resistance of cancer.
    Zhu YX; Jia HR; Duan QY; Wu FG
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2021 Sep; 13(5):e1715. PubMed ID: 33860622
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted nanomedicine for cancer therapeutics: Towards precision medicine overcoming drug resistance.
    Bar-Zeev M; Livney YD; Assaraf YG
    Drug Resist Updat; 2017 Mar; 31():15-30. PubMed ID: 28867241
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent strategies to overcome breast cancer resistance.
    Khan MM; Yalamarty SSK; Rajmalani BA; Filipczak N; Torchilin VP
    Crit Rev Oncol Hematol; 2024 May; 197():104351. PubMed ID: 38615873
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of integrated cancer nanomedicine in overcoming drug resistance.
    Iyer AK; Singh A; Ganta S; Amiji MM
    Adv Drug Deliv Rev; 2013 Nov; 65(13-14):1784-802. PubMed ID: 23880506
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improvement of conventional anti-cancer drugs as new tools against multidrug resistant tumors.
    Dallavalle S; Dobričić V; Lazzarato L; Gazzano E; Machuqueiro M; Pajeva I; Tsakovska I; Zidar N; Fruttero R
    Drug Resist Updat; 2020 May; 50():100682. PubMed ID: 32087558
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Different strategies to overcome multidrug resistance in cancer.
    Saraswathy M; Gong S
    Biotechnol Adv; 2013 Dec; 31(8):1397-407. PubMed ID: 23800690
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nanodrug delivery in reversing multidrug resistance in cancer cells.
    Kapse-Mistry S; Govender T; Srivastava R; Yergeri M
    Front Pharmacol; 2014; 5():159. PubMed ID: 25071577
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic strategies to overcome taxane resistance in cancer.
    Das T; Anand U; Pandey SK; Ashby CR; Assaraf YG; Chen ZS; Dey A
    Drug Resist Updat; 2021 Mar; 55():100754. PubMed ID: 33691261
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Insight on Multidrug Resistance and Nanomedicine Approaches to Overcome MDR.
    Mohammad IS; He W; Yin L
    Crit Rev Ther Drug Carrier Syst; 2020; 37(5):473-509. PubMed ID: 33389848
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nanomedicine to Overcome Multidrug Resistance Mechanisms in Colon and Pancreatic Cancer: Recent Progress.
    Ortíz R; Quiñonero F; García-Pinel B; Fuel M; Mesas C; Cabeza L; Melguizo C; Prados J
    Cancers (Basel); 2021 Apr; 13(9):. PubMed ID: 33923200
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multidrug resistance: Physiological principles and nanomedical solutions.
    Kunjachan S; Rychlik B; Storm G; Kiessling F; Lammers T
    Adv Drug Deliv Rev; 2013 Nov; 65(13-14):1852-1865. PubMed ID: 24120954
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The reversal of chemotherapy-induced multidrug resistance by nanomedicine for cancer therapy.
    Liu S; Khan AR; Yang X; Dong B; Ji J; Zhai G
    J Control Release; 2021 Jul; 335():1-20. PubMed ID: 33991600
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multifunctional nanoplatforms co-delivering combinatorial dual-drug for eliminating cancer multidrug resistance.
    Wei X; Song M; Li W; Huang J; Yang G; Wang Y
    Theranostics; 2021; 11(13):6334-6354. PubMed ID: 33995661
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nanodelivery systems: An efficient and target-specific approach for drug-resistant cancers.
    Ashique S; Garg A; Hussain A; Farid A; Kumar P; Taghizadeh-Hesary F
    Cancer Med; 2023 Sep; 12(18):18797-18825. PubMed ID: 37668041
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Engineering Nanomedicines to Overcome Multidrug Resistance in Cancer Therapy.
    Beretta GL; Cavalieri F
    Curr Med Chem; 2016; 23(1):3-22. PubMed ID: 26438248
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.